Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05218850 · ClinicalTrials.gov registry record · Phase 1
The Use of Butyrate Therapy in Pediatric Ulcerative Colitis
A Phase 1 study of Ulcerative Colitis, sponsored by Children's Hospital Los Angeles.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT05218850 is a Phase 1 study of Ulcerative Colitis that is actively recruiting participants, run by Children's Hospital Los Angeles. The registered enrollment target is 10 participants, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05218850, a Phase 1 study of Ulcerative Colitis, is actively recruiting participants, sponsored by Children's Hospital Los Angeles.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Butyrate is an important metabolite produced by the gut microbiome and has been shown as a helpful therapy in ulcerative colitis. This is a feasibility study to determine the efficacy of butryate enemas in pediatric ulcerative colitis.
Conditions Studied
Interventions
- DRUG Butyrate
Study Locations (1)
California
- Children's Hospital Los Angeles - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-06-29 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05218850
The ClinicalTrials.gov registry entry for NCT05218850 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (100% lower). The listed sponsor is Children's Hospital Los Angeles, which has 119 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 1 intervention - of which Butyrate is the first listed.
NCT05218850 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05218850 about?
NCT05218850 is a clinical study titled "The Use of Butyrate Therapy in Pediatric Ulcerative Colitis". Butyrate is an important metabolite produced by the gut microbiome and has been shown as a helpful therapy in ulcerative colitis. This is a feasibility study to determine the efficacy of butryate enemas in pediatric ulcerative colitis.
What is the current status of trial NCT05218850?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2022-06-29. Estimated completion is 2027-06-30.
What conditions does trial NCT05218850 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT05218850?
The interventions under investigation include: Butyrate (DRUG).
Who is sponsoring clinical trial NCT05218850?
This trial is sponsored by Children's Hospital Los Angeles, which has 119 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05218850 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
R-3750 in Patients With Mild to Moderate Ulcerative Colitis
RECRUITING · Phase 1
-
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
RECRUITING · Phase 1
-
CP101 for the Treatment of Ulcerative Colitis
ACTIVE NOT RECRUITING · Phase 1
-
Angiographic Delivery of AD-MSC for Ulcerative Colitis
ACTIVE NOT RECRUITING · Phase 1
-
Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis
COMPLETED · Phase 1
-
Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.